Eivind Grong1, Hallvard Græslie2, Bjørn Munkvold3, Ingerid Brænne Arbo4, Bård Erik Kulseng3,5, Helge L Waldum3,6, Ronald Mårvik3,5,7. 1. Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), PB 8905, N-7491, Trondheim, Norway. eivig@stud.ntnu.no. 2. Department of Surgery, Namsos Hospital, Nord Trøndelag Health Trust, Namsos, Norway. 3. Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), PB 8905, N-7491, Trondheim, Norway. 4. Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. 5. Centre for Obesity Research and Innovation, HMN (ObeCe), St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 6. Department of Gastroenterology and Hepatology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 7. Department of Gastrointestinal Surgery and Norwegian National Advisory Unit on Advanced Laparoscopic Surgery (NSALK), St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Abstract
BACKGROUND: Recent investigations have linked elevated gastrin levels to the improvement of type 2 diabetes mellitus (T2DM). Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are effective treatments for T2DM, but it is not known if this is related to postoperative alterations of gastrin secretion. METHODS: Twenty women previously operated with RYGB or SG and 13 female controls were enrolled and evaluated for body mass index, lipids, C-peptide, HbA1c, and anti-H. pylori IgG. Glucose, gastrin, insulin, and glucagon-like peptide 1 (GLP-1) concentrations were measured before and 30, 60, 90, and 120 min after ingestion of a protein-rich mixed meal. RESULTS: Six participants primarily selected were excluded due to usage of proton pump inhibitors, positive H.pylori IgG, or history of T2DM, yielding the following groups: RYGB (n = 9), SG (n = 8), and controls (n = 10). There were no differences in age, body mass index, HbA1c, or C-peptide levels between groups. RYGB had significantly lower area under the curve (AUC) for glucose during the test compared to controls (p = 0.013). RYGB showed lower serum gastrin levels compared to SG and controls (p < 0.05 for all). There was a non-significant increased gastrin release in SG compared to controls (p = 0.091). For SG and controls, there was a negative correlation between glucose and gastrin response (p = 0.0043). CONCLUSION: Gastrin secretion is diminished after RYGB. Hypergastrinemia was not present after SG, but a tendency of enhanced gastrin secretion was observed. These findings require further investigation in prospective studies.
BACKGROUND: Recent investigations have linked elevated gastrin levels to the improvement of type 2 diabetes mellitus (T2DM). Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are effective treatments for T2DM, but it is not known if this is related to postoperative alterations of gastrin secretion. METHODS: Twenty women previously operated with RYGB or SG and 13 female controls were enrolled and evaluated for body mass index, lipids, C-peptide, HbA1c, and anti-H. pylori IgG. Glucose, gastrin, insulin, and glucagon-like peptide 1 (GLP-1) concentrations were measured before and 30, 60, 90, and 120 min after ingestion of a protein-rich mixed meal. RESULTS: Six participants primarily selected were excluded due to usage of proton pump inhibitors, positive H.pylori IgG, or history of T2DM, yielding the following groups: RYGB (n = 9), SG (n = 8), and controls (n = 10). There were no differences in age, body mass index, HbA1c, or C-peptide levels between groups. RYGB had significantly lower area under the curve (AUC) for glucose during the test compared to controls (p = 0.013). RYGB showed lower serum gastrin levels compared to SG and controls (p < 0.05 for all). There was a non-significant increased gastrin release in SG compared to controls (p = 0.091). For SG and controls, there was a negative correlation between glucose and gastrin response (p = 0.0043). CONCLUSION:Gastrin secretion is diminished after RYGB. Hypergastrinemia was not present after SG, but a tendency of enhanced gastrin secretion was observed. These findings require further investigation in prospective studies.
Authors: Eunyoung Choi; Joseph T Roland; Brittney J Barlow; Ryan O'Neal; Amy E Rich; Ki Taek Nam; Chanjuan Shi; James R Goldenring Journal: Gut Date: 2014-01-31 Impact factor: 23.059
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: C Dirksen; M Damgaard; K N Bojsen-Møller; N B Jørgensen; U Kielgast; S H Jacobsen; L S Naver; D Worm; J J Holst; S Madsbad; D L Hansen; J L Madsen Journal: Neurogastroenterol Motil Date: 2013-01-29 Impact factor: 3.598
Authors: Nora Hedbäck; Morten Hindsø; Kirstine N Bojsen-Møller; Adelaide K Linddal; Nils B Jørgensen; Carsten Dirksen; Andreas Møller; Viggo B Kristiansen; Bolette Hartmann; Jens J Holst; Maria S Svane; Sten Madsbad Journal: Front Nutr Date: 2022-04-29
Authors: C C Van Olden; A W Van de Laar; A S Meijnikman; O Aydin; N Van Olst; J B Hoozemans; L M De Brauw; S C Bruin; Y I Z Acherman; J Verheij; J E Pyykkö; M Hagedoorn; R Sanderman; N C Bosma; V Tremaroli; A Lundqvist; L E Olofsson; H Herrema; D Lappa; S Hjorth; J Nielsen; T Schwartz; A K Groen; M Nieuwdorp; F Bäckhed; V E A Gerdes Journal: J Intern Med Date: 2020-09-29 Impact factor: 8.989